Flumazenil
Back to searchMolecule Structure
Scientific Name
Flumazenil
Description of the Drug
Flumazenil is a benzodiazepine antagonist that is used for the complete or partial reversal of the sedative effects caused by benzodiazepines in various clinical settings, such as induced general anesthesia for diagnostic and therapeutic procedures.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01205
http://www.drugbank.ca/drugs/DB01205
Brand Name(s)
Anexate, Flumazenil, Flumazepil, Mazicon, Romazicon
Company Owner(s)
Hoffmann La Roche Inc, Fresenius Kabi Usa Llc, Sandoz Inc, Sagent Pharmaceuticals Inc, Hikma Farmaceutica (Portugal) Sa, Rising Pharma Holding Inc, Dr Reddys Laboratories Ltd, Hikma Pharmaceuticals Usa Inc, Baxter Healthcare Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| GABA-A receptor; anion channel | PROTEIN COMPLEX GROUP | ALLOSTERIC ANTAGONIST | CHEMBL2093872 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL79030 | |
| PharmGKB | PA449659 | |
| Human Metabolome Database | HMDB0015336 | |
| DrugBank | DB01205 | |
| PubChem: Thomson Pharma | 14849666 | |
| PubChem | 3373 | |
| Mcule | MCULE-2830706565 | |
| LINCS | LSM-4228 | |
| Nikkaji | J23.594F | |
| PDBe | FYP | |
| BindingDB | 26263 | |
| EPA CompTox Dashboard | DTXSID2023064 | |
| DrugCentral | 1195 | |
| ChemicalBook | CB9208108 | |
| Guide to Pharmacology | 4192 | 4367 |
| rxnorm | FLUMAZENIL | |
| PubChem: Drugs of the Future | 12013048 | |
| KEGG Ligand | C07825 | |
| ChEBI | 5103 | |
| ZINC | ZINC000000001464 |
